Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:diamino acid
go back to main search page
Accession:CHEBI:35987 term browser browse the term
Definition:Any amino acid carrying two amino groups.
Synonyms:cyclic_relationship: is_conjugate_acid_of CHEBI:59561


show annotations for term's descendants           Sort by:
2,4-diaminobutyric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CASP3 caspase 3 multiple interactions EXP [beta-N-methylamino-L-alanine co-treated with 2,4-diaminobutyric acid] results in increased activity of CASP3 protein CTD PMID:28634653 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G COX6B1 cytochrome c oxidase subunit 6B1 multiple interactions EXP [beta-N-methylamino-L-alanine co-treated with 2,4-diaminobutyric acid] results in increased expression of COX6B1 mRNA CTD PMID:28634653 NCBI chr19:35,648,323...35,658,782
Ensembl chr19:35,648,323...35,658,782 		JBrowse link
G CTSB cathepsin B multiple interactions EXP [beta-N-methylamino-L-alanine co-treated with 2,4-diaminobutyric acid] results in increased activity of CTSB protein CTD PMID:28634653 NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533 		JBrowse link
G CTSL cathepsin L multiple interactions EXP [beta-N-methylamino-L-alanine co-treated with 2,4-diaminobutyric acid] results in increased activity of CTSL protein CTD PMID:28634653 NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469 		JBrowse link
G GPT2 glutamic--pyruvic transaminase 2 multiple interactions EXP [beta-N-methylamino-L-alanine co-treated with 2,4-diaminobutyric acid] results in increased expression of GPT2 mRNA CTD PMID:28634653 NCBI chr16:46,884,362...46,931,289
Ensembl chr16:46,884,362...46,931,289 		JBrowse link
goralatide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACE angiotensin I converting enzyme decreases expression
increases expression
multiple interactions		 ISO goralatide results in decreased expression of ACE mRNA
goralatide results in increased expression of ACE mRNA
[BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA]		 CTD PMID:20096676 PMID:33007385 NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380 		JBrowse link
G ACE2 angiotensin converting enzyme 2 multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein] CTD PMID:33007385 NCBI chr  X:15,518,197...15,607,211
Ensembl chr  X:15,494,566...15,607,236 		JBrowse link
G ACTA2 actin alpha 2, smooth muscle multiple interactions ISO
EXP		 [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]
goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]		 CTD PMID:31181250 PMID:33007385 NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339 		JBrowse link
G AGT angiotensinogen multiple interactions EXP
ISO		 [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein]
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein]		 CTD PMID:31181250 PMID:33007385 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576 		JBrowse link
G AGTR1 angiotensin II receptor type 1 multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein] CTD PMID:33007385 NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008 		JBrowse link
G BDKRB1 bradykinin receptor B1 multiple interactions
affects abundance		 ISO [BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide
BDKRB1 protein affects the abundance of goralatide		 CTD PMID:20096676 NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967 		JBrowse link
G CDH1 cadherin 1 multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein] CTD PMID:33007385 NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537 		JBrowse link
G COL3A1 collagen type III alpha 1 chain multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein] CTD PMID:33007385 NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746 		JBrowse link
G GLI1 GLI family zinc finger 1 multiple interactions ISO
EXP		 [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]		 CTD PMID:31181250 NCBI chr12:57,459,785...57,472,268
Ensembl chr12:57,459,785...57,472,268 		JBrowse link
G GLI2 GLI family zinc finger 2 multiple interactions EXP
ISO		 [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]		 CTD PMID:31181250 NCBI chr 2:120,735,868...120,992,653
Ensembl chr 2:120,735,623...120,992,653 		JBrowse link
G GLI3 GLI family zinc finger 3 multiple interactions ISO
EXP		 [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]		 CTD PMID:31181250 NCBI chr 7:41,960,949...42,264,268
Ensembl chr 7:41,960,949...42,264,100 		JBrowse link
G MAS1 MAS1 proto-oncogene, G protein-coupled receptor multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein] CTD PMID:33007385 NCBI chr 6:159,888,787...159,917,447
Ensembl chr 6:159,890,988...159,917,447 		JBrowse link
G PTCH1 patched 1 multiple interactions ISO
EXP		 [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]		 CTD PMID:31181250 NCBI chr 9:95,442,980...95,516,971
Ensembl chr 9:95,442,980...95,517,057 		JBrowse link
G SHH sonic hedgehog signaling molecule multiple interactions ISO
EXP		 [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]		 CTD PMID:31181250 NCBI chr 7:155,799,980...155,812,463
Ensembl chr 7:155,799,980...155,812,463 		JBrowse link
G SMO smoothened, frizzled class receptor multiple interactions EXP
ISO		 [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]		 CTD PMID:31181250 NCBI chr 7:129,188,633...129,213,545
Ensembl chr 7:129,188,633...129,213,545 		JBrowse link
G VIM vimentin multiple interactions ISO goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein] CTD PMID:33007385 NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593 		JBrowse link
L-homoarginine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLCO4C1 solute carrier organic anion transporter family member 4C1 increases export EXP SLCO4C1 protein results in increased export of Homoarginine CTD PMID:30865704 NCBI chr 5:102,233,986...102,296,284
Ensembl chr 5:102,233,986...102,296,284 		JBrowse link
L-lysine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G EGF epidermal growth factor multiple interactions ISO [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine] CTD PMID:22689575 NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766 		JBrowse link
lisinopril dihydrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACE angiotensin I converting enzyme decreases activity EXP Lisinopril analog results in decreased activity of ACE protein CTD PMID:22200082 NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380 		JBrowse link
G ACE2 angiotensin converting enzyme 2 increases expression
multiple interactions
increases activity		 ISO Lisinopril results in increased expression of ACE2 mRNA
ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]
Lisinopril results in increased activity of ACE2 protein		 CTD PMID:15897343 PMID:16221218 PMID:27649628 NCBI chr  X:15,518,197...15,607,211
Ensembl chr  X:15,494,566...15,607,236 		JBrowse link
G ACHE acetylcholinesterase (Yt blood group) multiple interactions ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]		 CTD PMID:23060470 PMID:31710167 NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974 		JBrowse link
G AGT angiotensinogen decreases expression
multiple interactions
affects metabolic processing
decreases secretion
increases secretion
affects response to substance
increases expression		 EXP
ISO		 Lisinopril results in decreased expression of AGT protein
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein
[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)]
Lisinopril results in decreased secretion of AGT protein
Lisinopril results in increased secretion of AGT protein alternative form
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in increased expression of AGT mRNA		 CTD PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 More... NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576 		JBrowse link
G BCL2 BCL2 apoptosis regulator decreases expression EXP Lisinopril results in decreased expression of BCL2 CTD PMID:10075388 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G CD2AP CD2 associated protein multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein] CTD PMID:16636307 NCBI chr 6:47,477,789...47,627,263
Ensembl chr 6:47,477,789...47,627,263 		JBrowse link
G EDN1 endothelin 1 decreases secretion EXP Lisinopril results in decreased secretion of EDN1 protein CTD PMID:19079593 NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194 		JBrowse link
G GH1 growth hormone 1 multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr17:63,917,203...63,918,839
Ensembl chr17:63,917,200...63,918,839 		JBrowse link
G HAVCR1 hepatitis A virus cellular receptor 1 multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:19225054 NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396 		JBrowse link
G HLA-G major histocompatibility complex, class I, G affects expression EXP Lisinopril affects the expression of HLA-G mRNA CTD PMID:25811541 NCBI chr 6:29,826,474...29,831,021
Ensembl chr 6:29,826,967...29,831,125 		JBrowse link
G HPSE heparanase multiple interactions ISO [Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein] CTD PMID:19429930 NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153 		JBrowse link
G IGFBP1 insulin like growth factor binding protein 1 increases expression EXP Lisinopril results in increased expression of IGFBP1 protein CTD PMID:9663927 NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660 		JBrowse link
G MMP2 matrix metallopeptidase 2 multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] CTD PMID:20051877 NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691 		JBrowse link
G MPO myeloperoxidase multiple interactions ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein] CTD PMID:23060470 NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935 		JBrowse link
G NOS2 nitric oxide synthase 2 multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529 		JBrowse link
G NPHS1 NPHS1 adhesion molecule, nephrin multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein] CTD PMID:16636307 PMID:19293598 NCBI chr19:35,862,915...35,869,357
Ensembl chr19:35,825,964...35,869,287 		JBrowse link
G NPHS2 NPHS2 stomatin family member, podocin multiple interactions ISO Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein] CTD PMID:16636307 NCBI chr 1:179,550,539...179,575,948
Ensembl chr 1:179,550,539...179,575,952 		JBrowse link
G NPPA natriuretic peptide A decreases expression EXP Lisinopril results in decreased expression of NPPA protein CTD PMID:8393685 NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345 		JBrowse link
G REN renin increases expression
multiple interactions		 EXP
ISO		 Lisinopril results in increased expression of REN protein
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA
Lisinopril results in increased expression of REN mRNA		 CTD PMID:2550029 PMID:8915971 PMID:16221218 NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324 		JBrowse link
G TIMP1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein] CTD PMID:20051877 NCBI chr  X:47,582,436...47,586,789
Ensembl chr  X:47,582,408...47,586,789 		JBrowse link
G VEGFA vascular endothelial growth factor A multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein] CTD PMID:19293598 NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
royal jelly term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BAX BCL2 associated X, apoptosis regulator multiple interactions ISO royal jelly inhibits the reaction [Fluorides results in decreased expression of BAX protein] CTD PMID:34227456 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA]
royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein]		 CTD PMID:30896085 PMID:34227456 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BDNF brain derived neurotrophic factor multiple interactions ISO royal jelly inhibits the reaction [Fluorides results in decreased expression of BDNF protein] CTD PMID:34227456 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058 		JBrowse link
G CASP3 caspase 3 multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA]
royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein]		 CTD PMID:30896085 PMID:34227456 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CASP6 caspase 6 multiple interactions ISO royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP6 protein] CTD PMID:34227456 NCBI chr 4:109,664,388...109,709,767
Ensembl chr 4:109,688,622...109,703,583 		JBrowse link
G CASP9 caspase 9 multiple interactions ISO royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP9 protein] CTD PMID:34227456 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534 		JBrowse link
G CAT catalase multiple interactions ISO royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein]
royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]		 CTD PMID:20369241 PMID:30896085 PMID:34227456 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CCND1 cyclin D1 multiple interactions ISO royal jelly inhibits the reaction [phenylhydrazine affects the expression of CCND1 mRNA] CTD PMID:35099105 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 		JBrowse link
G E2F1 E2F transcription factor 1 multiple interactions ISO royal jelly inhibits the reaction [Paclitaxel results in increased expression of E2F1 mRNA] CTD PMID:27496854 NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385 		JBrowse link
G ESR1 estrogen receptor 1 multiple interactions
affects binding
increases activity		 EXP Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein]
royal jelly results in increased activity of ESR1 protein		 CTD PMID:15946813 PMID:17287592 NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619 		JBrowse link
G ESR2 estrogen receptor 2 multiple interactions
affects binding		 EXP Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein] CTD PMID:15946813 PMID:17287592 NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta multiple interactions ISO royal jelly inhibits the reaction [Fluorides results in increased expression of GSK3B protein] CTD PMID:34227456 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G INS-IGF2 INS-IGF2 readthrough multiple interactions ISO royal jelly inhibits the reaction [Fructose results in increased expression of INS1 protein] CTD PMID:18981581 NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209 		JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression		 ISO royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA]
royal jelly results in decreased expression of MYC mRNA
royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA]		 CTD PMID:27496854 PMID:35099105 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 multiple interactions ISO royal jelly inhibits the reaction [Fluorides results in decreased expression of NFE2L2 protein] CTD PMID:34227456 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756 		JBrowse link
G PCNA proliferating cell nuclear antigen multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein] CTD PMID:30896085 NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626 		JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions ISO royal jelly inhibits the reaction [Fluorides results in increased expression of RELA protein] CTD PMID:34227456 NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090 		JBrowse link
G TFF1 trefoil factor 1 increases expression EXP royal jelly results in increased expression of TFF1 mRNA CTD PMID:15946813 NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535 		JBrowse link
G TP53 tumor protein p53 multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA] CTD PMID:30896085 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538 		JBrowse link
G VEGFA vascular endothelial growth factor A increases expression EXP
ISO		 royal jelly results in increased expression of VEGFA mRNA CTD PMID:15946813 PMID:17287592 NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26050
    role 25966
      application 25188
        NMR chemical shift reference compound 20305
          ammonia 19959
            organic amino compound 19959
              amino acid 17173
                diamino acid 58
                  (2R,5S)-2,5-diaminohexanoic acid 0
                  (3R)-3,6-diaminohexanoic acid 0
                  (3S)-3,6-diaminohexanoic acid 0
                  (3S)-3,7-diaminoheptanoic acid 0
                  (3S,5S)-3,5-diaminohexanoic acid 0
                  2,4-diaminobutyric acid + 5
                  2,4-diaminopentanoic acid + 0
                  2,6-diamino-7-hydroxy-azelaic acid 0
                  3-aminoalanine + 0
                  L-BMAA 0
                  lysine + 54
Path 2
Term Annotations click to browse term
  CHEBI ontology 26050
    subatomic particle 26025
      composite particle 26025
        hadron 26025
          baryon 26025
            nucleon 26025
              atomic nucleus 26025
                atom 26025
                  main group element atom 25850
                    main group molecular entity 25850
                      s-block molecular entity 25171
                        hydrogen molecular entity 24769
                          hydrides 22980
                            inorganic hydride 20499
                              pnictogen hydride 20440
                                nitrogen hydride 20216
                                  azane 19960
                                    ammonia 19959
                                      organic amino compound 19959
                                        amino acid 17173
                                          diamino acid 58
                                            (2R,5S)-2,5-diaminohexanoic acid 0
                                            (3R)-3,6-diaminohexanoic acid 0
                                            (3S)-3,6-diaminohexanoic acid 0
                                            (3S)-3,7-diaminoheptanoic acid 0
                                            (3S,5S)-3,5-diaminohexanoic acid 0
                                            2,4-diaminobutyric acid + 5
                                            2,4-diaminopentanoic acid + 0
                                            2,6-diamino-7-hydroxy-azelaic acid 0
                                            3-aminoalanine + 0
                                            L-BMAA 0
                                            lysine + 54
paths to the root